JP2017501227A5 - - Google Patents

Download PDF

Info

Publication number
JP2017501227A5
JP2017501227A5 JP2016560871A JP2016560871A JP2017501227A5 JP 2017501227 A5 JP2017501227 A5 JP 2017501227A5 JP 2016560871 A JP2016560871 A JP 2016560871A JP 2016560871 A JP2016560871 A JP 2016560871A JP 2017501227 A5 JP2017501227 A5 JP 2017501227A5
Authority
JP
Japan
Prior art keywords
composition
hours
acid
minutes
alginic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016560871A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501227A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/071664 external-priority patent/WO2015095793A1/en
Publication of JP2017501227A publication Critical patent/JP2017501227A/ja
Publication of JP2017501227A5 publication Critical patent/JP2017501227A5/ja
Pending legal-status Critical Current

Links

JP2016560871A 2013-12-19 2014-12-19 アルギン酸をベースとする抗菌性化合物を使用して炎症と疾患を阻害するための組成物及び方法 Pending JP2017501227A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361918445P 2013-12-19 2013-12-19
US61/918,445 2013-12-19
PCT/US2014/071664 WO2015095793A1 (en) 2013-12-19 2014-12-19 Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020063444A Division JP2020125298A (ja) 2013-12-19 2020-03-31 アルギン酸をベースとする抗菌性化合物を使用して炎症と疾患を阻害するための組成物及び方法

Publications (2)

Publication Number Publication Date
JP2017501227A JP2017501227A (ja) 2017-01-12
JP2017501227A5 true JP2017501227A5 (OSRAM) 2017-12-07

Family

ID=53403777

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016560871A Pending JP2017501227A (ja) 2013-12-19 2014-12-19 アルギン酸をベースとする抗菌性化合物を使用して炎症と疾患を阻害するための組成物及び方法
JP2020063444A Pending JP2020125298A (ja) 2013-12-19 2020-03-31 アルギン酸をベースとする抗菌性化合物を使用して炎症と疾患を阻害するための組成物及び方法
JP2022017393A Pending JP2022070924A (ja) 2013-12-19 2022-02-07 アルギン酸をベースとする抗菌性化合物を使用して炎症と疾患を阻害するための組成物及び方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020063444A Pending JP2020125298A (ja) 2013-12-19 2020-03-31 アルギン酸をベースとする抗菌性化合物を使用して炎症と疾患を阻害するための組成物及び方法
JP2022017393A Pending JP2022070924A (ja) 2013-12-19 2022-02-07 アルギン酸をベースとする抗菌性化合物を使用して炎症と疾患を阻害するための組成物及び方法

Country Status (15)

Country Link
US (3) US11337989B2 (OSRAM)
EP (2) EP3082826B1 (OSRAM)
JP (3) JP2017501227A (OSRAM)
KR (1) KR102407408B1 (OSRAM)
CN (2) CN106029078A (OSRAM)
AU (2) AU2014368971B2 (OSRAM)
BR (1) BR112016014506B1 (OSRAM)
DK (1) DK3082826T3 (OSRAM)
ES (1) ES2790703T3 (OSRAM)
IL (1) IL246146B2 (OSRAM)
MX (2) MX2016008023A (OSRAM)
NZ (1) NZ722215A (OSRAM)
RU (1) RU2691950C1 (OSRAM)
WO (1) WO2015095793A1 (OSRAM)
ZA (1) ZA201604862B (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA115876C2 (uk) 2012-06-13 2018-01-10 Івофем, Інк. Композиція і спосіб підвищення ефективності бактерицидних засобів контрацепції
RU2691950C1 (ru) 2013-12-19 2019-06-19 Ивофем, Инк. Композиции и способы ингибирования воспаления и заболеваний с применением антимикробного соединения на основе альгиновой кислоты
DE102017110168A1 (de) 2016-05-25 2017-11-30 Samsung Electronics Co., Ltd. Elektronische Vorrichtung mit NFC-Antenne
WO2018049326A1 (en) * 2016-09-12 2018-03-15 Evofem Biosciences, Inc. Combination gel for sexually transmitted infections
WO2018067568A1 (en) * 2016-10-04 2018-04-12 Evofem Biosciences, Inc. Method of treatment and prevention of bacterial vaginosis
EP4422640A4 (en) * 2021-10-28 2025-11-19 Evofem Inc FAST-DISSOLVING VAGINAL FILM WITH CONTRACEPTIVE ACTION AND PREVENTION OF SEXUALLY TRANSMITTED INFECTION

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1213323B (it) 1986-08-07 1989-12-20 Crinos Industria Farmaco Composizione per uso locale ad atti vita' spermicida virulicida ,disinfettante e/o battericida
US4999342A (en) 1988-08-16 1991-03-12 Ortho Pharmaceutical Corporation Long lasting contraceptive suppository composition and methods of use
JP3202365B2 (ja) 1992-12-04 2001-08-27 株式会社紀文フードケミファ オリゴマンヌロン酸を重合度によって分離する方法
US5592949A (en) 1994-06-29 1997-01-14 Moench; Thomas R. Device for acidic buffering and method for inactivation of pathogens
US5667492A (en) 1994-10-07 1997-09-16 Columbia Laboratories, Inc. Use and composition of an anti-sexually transmitted diseases formulation
FR2728464B1 (fr) 1994-12-22 1997-04-30 Innothera Lab Sa Forme galenique unitaire, son procede d'obtention et ses utilisations
US6093394A (en) 1997-04-11 2000-07-25 Gynelogix, Inc. Vaginal lactobacillus medicant
WO2001038284A1 (en) 1999-11-24 2001-05-31 Cargill Dow Llc Improved lactic acid processing; methods; arrangements; and, products
CA2402589C (en) * 2000-03-07 2011-02-01 Sanjay Garg Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa
JP2009102407A (ja) * 2001-03-08 2009-05-14 Rohto Pharmaceut Co Ltd Gリッチなアルギン酸含有組成物
US20020177624A1 (en) 2001-03-16 2002-11-28 Calvin Hanna Acetate-lactate buffering vaginal gel and for method of making same and treating bacterial vaginosis
ITMI20010913A1 (it) 2001-05-04 2002-11-04 Univ Pavia Composizioni a rilascio controllato di acido lattico a livello vaginale
CA2449247A1 (en) * 2001-06-11 2002-12-19 Merck & Co., Inc. A method for treating inflammatory diseases by administering a ppar-delta agonist
US20130150810A1 (en) 2002-04-30 2013-06-13 The Population Council, Inc. Intravaginal ring for the delivery of unique combinations of antimicrobial compositions
WO2004011032A1 (ja) 2002-07-26 2004-02-05 Mikasa Seiyaku Co., Ltd. 外用剤
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
EP1635847B1 (en) 2003-06-13 2019-07-31 IDH Holding ApS Treatment of symptoms associated with bacterial vaginosis
US20050272700A1 (en) 2004-05-10 2005-12-08 Servet Buyuktimkin Topical treatment and prevention of human papilloma virus (HPV) infection
RU2257197C1 (ru) 2004-05-12 2005-07-27 Дулькис Мария Дмитриевна Вагинальные суппозитории, обладающие контрацептивным действием
UA93354C2 (ru) 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Местный противовирусный препарат
GB2456476A (en) * 2006-11-10 2009-07-22 Rohto Pharma Composition for skin or mucosal application
US7659259B2 (en) * 2006-12-21 2010-02-09 Bausch & Lomb Incorporated Method of treating inflammation of the eye
WO2008119518A1 (en) 2007-03-30 2008-10-09 Laccure Ab Use of oligomers of lactic acid in the treatment of gynaecological disorders
AU2008256689A1 (en) 2007-05-24 2008-12-04 New York Blood Center Inc. Rapidly dispersible vaginal tablet that provides a bioadhesive gel
TW200927141A (en) 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
BRPI0907317A2 (pt) 2008-04-16 2019-08-27 Cipla Ltd composição farmacêutica e método para fabricar uma composição farmacêutica tópica em gel, espuma e em spray
WO2009155118A1 (en) * 2008-05-30 2009-12-23 Reprotect, Inc. Compositions and methods for inactivation of pathogens at genital tract surfaces
EP2130531A1 (en) 2008-06-04 2009-12-09 Rolf Kullgren AB Vaginal suppository comprising lactic acid
WO2010142761A1 (en) 2009-06-10 2010-12-16 Ultimorphix Technologies B.V. The succinate of tenofovir disoproxil
MX2013012745A (es) * 2011-05-02 2014-12-05 Aptalis Pharmatech Inc Composiciones en forma de comprmido de disolución rápida para administración vaginal.
EP2725904B1 (en) 2011-06-28 2024-12-11 Chemo Research SL High dosage mucoadhesive metronidazole aqueous-based gel formulations their use to treat bacterial vaginosis
UA115876C2 (uk) 2012-06-13 2018-01-10 Івофем, Інк. Композиція і спосіб підвищення ефективності бактерицидних засобів контрацепції
WO2015027071A1 (en) 2013-08-21 2015-02-26 Georgia Regents Research Institute, Inc. Gpr81 agonists and methods thereof for promoting production of secretory iga
RU2691950C1 (ru) 2013-12-19 2019-06-19 Ивофем, Инк. Композиции и способы ингибирования воспаления и заболеваний с применением антимикробного соединения на основе альгиновой кислоты
US9801839B2 (en) 2014-02-28 2017-10-31 Macfarlane Burnet Institute For Medical Research And Public Health Pty Ltd Therapeutic method

Similar Documents

Publication Publication Date Title
JP2017501227A5 (OSRAM)
JP2016532722A5 (OSRAM)
MX2020005942A (es) Delgada pelicula oral con alta carga de agente activo.
JP2016503058A5 (OSRAM)
JP2017514850A5 (OSRAM)
UA105766C2 (uk) Фармацевтична композиція, яка містить сіль стронцію, вітамін d і циклодекстрин
NZ612686A (en) Sublingual films
JP2016534153A5 (OSRAM)
JP2014505733A5 (OSRAM)
JP2014240439A5 (OSRAM)
JP2015500794A5 (OSRAM)
MX2016000727A (es) Composicion farmaceutica acuosa liquida que contiene derivados de ciclodextrina eterificada con conservante.
RU2013134257A (ru) Водная композиция для ухода за полостью рта, включающая ксантановую камедь, целлюлозную камедь и карбомер
PH12013500923A1 (en) Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative
RU2016129069A (ru) Композиции и способы ингибирования воспаления и заболеваний с применением антимикробного соединения на основе альгиновой кислоты
RU2013113222A (ru) Способы лечения или профилактики тромбообразования или эмболии
RU2013134269A (ru) Полимерные системы
PH12015501312B1 (en) Solid dispersion with improved solubility comprising tetrazole derivative as an active ingredient
RU2014119858A (ru) Применение мелатонина для лечения и/или предотвращения мукозита
RU2012134065A (ru) Альфа-2 адренергический агонист, обладающий эффектом длительного снижения внутриглазного давления
JP2014510156A5 (OSRAM)
MX2013004117A (es) Formulacion farmaceutica para inhibidores de histona desacetilasa.
AR085273A1 (es) Formulacion liquida libre de propelente que comprende una droga antimuscarinica
JP2015519398A5 (OSRAM)
JP2015519395A5 (OSRAM)